Texas Compassionate Use Program Analysis: Fixing the Program Doesn't Fix the Competition

Daniel Kief

Daniel Kief

— 7 min read
Share

Texas ran a medical cannabis program more restrictive than comparator states for a decade: three dispensing organizations, all in central Texas, selling mostly edibles, tinctures, and beverages capped at 0.5–1% THC by weight, with no overnight product storage allowed outside the home dispensary. A 2024 state-commissioned evaluation found patient participation at 0.22% of population, well below the 5.32% average for medical-only states in its own comparison table. House Bill 46, effective September 2025, began fixing that: vaporizers and other non-smoked inhalation, expanded qualifying conditions, satellite storage, and a path from 3 licensed dispensing organizations to 15. Texas has also moved against the hemp market TCUP competes with, on two separate fronts of its own. None of that makes Texas the next Florida. It's still capped at 10mg THC per dose with no raw flower, prescribers remain scarce, and a real slice of Texas cannabis demand already crosses into New Mexico — a competitor no hemp law touches.

Market Overview

Senate Bill 339 created the Texas Compassionate Use Program (TCUP) in 2015, limited to intractable epilepsy, requiring two physicians' concurrence, and capping THC at 0.5% by weight. The program launched in 2017 with 12 patients. House Bill 1535 (2021) expanded eligibility to all cancer diagnoses and PTSD and raised the cap to 1%. Growth from there was real but narrow: a 2024 evaluation commissioned by DPS and conducted by Weeds LLC found patient participation at just 0.22% of population as of 2023, well below the 5.32% average for medical-only states in the report's own comparison table.

The report's central finding was structural: Texas's three dispensing organizations (Texas Original, Goodblend, Fluent TX) were all clustered within about an hour of Austin, each required to grow, process, and dispense from a single address with no overnight storage allowed elsewhere. Remote pickup locations had to return unsold product the same day, capping their reach to a half-day's drive and leaving 94.5% of counties with no access at all. In 2022, Texas Original served 73% of patients and 77% of units fulfilled; Goodblend served most of the rest; Fluent TX was functionally inoperable. A second drag: registered retail hemp locations grew from 710 (2020) to 4,468 (mid-2023) — a market the evaluation calls "mostly unregulated" relative to the medical program — correlating with prescription-unit growth falling from 445% (2020) to a projected 21% (2023).

House Bill 46, signed June 2025 and effective September 1, authorized non-smoked inhalation — vaporizers, inhalers, nebulizers, plus lotions, patches, and suppositories, still no smoking or raw flower — expanded qualifying conditions (chronic pain, TBI, Crohn's, terminal illness, hospice), replaced the 1% THC-by-weight cap with 10mg per dose and 1 gram of total THC per package, and directed DPS to add 12 dispensing licenses to the existing 3, for 15 total. It also authorized satellite storage for the first time — a real distinction, since satellites can hold inventory overnight while pickup sites still can't; as of March 2026, Texas Original had 4 approved satellites and 14 pickup sites. Hemp competition, meanwhile, is being squeezed by two separate Texas rules — one targeting THCA, the other delta-8 — on different legal footing: the delta-8 fight is over, decided by the Texas Supreme Court in the state's favor, while the THCA rule remains under a live appeal (more on this below).

The 15-License Expansion Is a 2027 Story, Not a 2026 One

The new licenses are conditional, not operational. DPS awarded 9 in December 2025 and 3 more by April 2026, then corrected a scoring error on May 8, swapping three companies out for three others. The corrected 12-name slate: Verano Texas, Trulieve TX, Texas Patient Access, Lonestar Compassionate Care Group, Lone Star Bioscience, PharmaCann, TexaRx, Dilatso, GTI (RISE), Bluebonnet Technologies, Sawtooth Texas, and Bayou City Medical Dispensary. Cresco Labs, one of the companies bumped, has disputed the correction and remains on the eligibility list. Conditional licensees get up to two years after final licensure to become operational — and DPS won't even invoice license fees until due diligence clears, so final licenses haven't issued and that clock hasn't started for anyone. The real near-term footprint is still the three incumbents, with Texas Original and Goodblend accounting for essentially all activity. A license count on paper is not built capacity.

Patients: Real Growth, but Discount the Headline Number

Texas's registry has grown steadily: 45,440 (Jan 2023) → 72,960 (Dec 2023) → 102,597 (Dec 2024) → 135,470 (Dec 2025) → 162,216 (Jul 2026), with two visible accelerations — September–October 2025 (~3.15%/month, HB 46's condition expansion) and a second stretch from May through July 2026 (2.2%, 3.2%, 2.9%) that picks up further once Texas Original's first vape device actually reached patients on June 3.

But Texas reports a lifetime cumulative count that never shrinks. Its own 2024 evaluation found that of 66,205 lifetime registrants, only 29,057 — about 44% — had filled a prescription in the trailing 12 months, and called that the better activity measure. That ratio predates HB 46 and can't be applied precisely to today's 162,216, but it shows Texas's headline number has historically overstated real participation by a wide margin.

Total Addressable Market

Texas's population is 31,709,821 (Census, July 2025), with around 24–25% under 18. Netting that and an estimated 18–20 cohort yields roughly 22.6 million adults 21 and over. At 18% participation and 1.0 g/day, full capture comes to a ~$8.2 billion adult-use-equivalent ceiling at $5.50/g.

A mature medical ceiling, assuming a quarter of that participation pool becomes actual patients at this framework's standard $2,008/year rate: roughly 1.02 million patients, ~$2.0 billion. Texas's raw enrollment of 162,216 is about 16% of the way there; applying the 2024 evaluation's own 44% utilization ratio would put it closer to 7%.

The Forecast

Florida is the obvious trajectory template, but the comparison needs tempering: Florida's Active ID Card series is a stock that can shrink on non-renewal; Texas's cumulative registry can only grow. That structural difference should make Texas's growth rate look higher than Florida's on mechanics alone, not lower — which makes it more notable, not less, that Texas is still running well behind. Some of the gap is also just base size: Florida in mid-2018 was 18 months into scaling from a small denominator, while Texas in 2026 is nine years in at 162,000, and compound growth mechanically decays as the base grows, independent of policy. Even allowing for both effects, the structural reasons below still carry real weight.

Florida legalized flower March 18, 2019; its Active ID Card counts over the clean pre-flower window (July 2018–January 2019) show roughly 9%/month compound growth. Texas's best months since HB 46 — 2.2–3.2%/month — sit well below that.

Four structural reasons argue for staying below the Florida curve rather than converging toward it:

  • Potency. Texas caps at 10mg THC per dose and 1 gram of total THC per package. Florida had no equivalent statutory dosage-unit ceiling in its pre-flower vape and oil market.
  • Prescribers, not just doors. The 2024 evaluation's recommendation was three-part: recruit physicians, expand dispensing footprints, add licenses. HB 46 did the second and third, not the first. It found a prescribing physician in only 63 of 254 counties and just 30 specialists for roughly 12,000 PTSD patients. DPS's own count put registered prescribers at 970 as of June 2026, against a physician workforce estimated at roughly 65,000 active direct-care doctors statewide — and TCUP only draws from enumerated specialties within that pool, so the real ratio is tighter still.
  • The hemp market Florida never faced. Delta-8/THCA retail is largely a post-2020 phenomenon — Florida's 2018–2019 growth happened in a competitive vacuum Texas doesn't have. Whitney Economics, in an industry-commissioned, pre-enforcement survey published to argue against a hemp ban Texas's governor ultimately vetoed in 2025, put the state's hemp-derived cannabinoid industry at roughly $5.5 billion, about $4.3 billion of it retail. Texas has since moved against both major categories itself, on two separate legal tracks: the delta-8 fight is over — the Texas Supreme Court sided with the state, and DSHS reinstated its controlled-substance scheduling in July — while a March 2026 rule effectively banning THCA flower and raising licensing fees sharply remains under active appeal, so that half isn't fully settled. A federal hemp redefinition is now enacted law too, with most restrictions delayed to December 11, 2026 by a bill signed September 2 — and it's meaningfully stricter than anything Texas has done, capturing compliant delta-9 edibles and beverages that Texas's own rules leave alone. If Texas's THCA rule survives its appeal and the federal delay isn't extended again, TCUP's real opportunity looks considerably more front-loaded than a "permanent competitor" framing suggests.
  • New Mexico. Texas has no adult-use market of its own, and a real, quantified share of Texas cannabis demand is already met across the border — a channel no hemp law touches. This publication's own analysis found New Mexico's 2025 sales ran about $158.6 million above the state's modeled resident demand (28% of actual sales), with the Doña Ana County cluster around El Paso alone generating $112 million in total 2025 sales, 19.7% of state revenue, an unusually large but unmeasured share of it plausibly attributable to El Paso-area demand since New Mexico doesn't record purchaser home state. West Texas Watchdogs independently verified the phenomenon on the ground, documenting Texas traffic in Glenrio, Tucumcari, Ruidoso, and Tatum, with Ruidoso and Tatum operators putting their own Texas customer share at 60–90%. That's demand TCUP is poorly positioned to recapture under its current prescription-gated, dose-capped structure.

Weighing real access improvements against those four headwinds: this analysis expects Texas to land closer to Iowa's and Kentucky's tier of legal capture — roughly 1.5–3% — than to Georgia's or Florida's, at least through this expansion cycle.

The Bottom Line

Texas spent a decade running a medical cannabis program more restrictive than comparator states, and HB 46 has begun fixing the access side of it. What it hasn't fixed: prescriber supply, and a fully legal New Mexico market pulling in well over $100 million a year that no domestic policy touches. Texas has moved hard against its hemp competitor on two fronts of its own, but a pending court appeal on one of those tracks means even that isn't fully settled. Against a modeled $8.2 billion ceiling and $2.0 billion mature-medical ceiling, Texas's near-term story is a program serving patients with no better option, while a much larger pool of demand keeps finding it elsewhere.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.